Advanced

Effects of sertindole on cognition in clozapine-treated schizophrenia patients

Nielsen, R. E.; Levander, Sten LU ; Thode, D. and Nielsen, J. (2012) In Acta Psychiatrica Scandinavica 126(1). p.31-39
Abstract
Nielsen RE, Levander S, Thode D, Nielsen J. Effects of sertindole on cognition in clozapine-treated schizophrenia patients. Objective: To assess the cognitive effects of sertindole augmentation in clozapine-treated patients diagnosed with schizophrenia. Cognition is secondary outcome of the trial. Method: A 12-week, double-blinded, randomized, placebo-controlled, augmentation study of patients treated with clozapine. Participants were randomized 1:1 to receive 16 mg of sertindole or placebo as adjunctive treatment to clozapine. Results: Participants displayed substantial cognitive deficits, ranging from 1.6 standard deviation below norms at baseline to more than three standard deviations on tests of response readiness and focused... (More)
Nielsen RE, Levander S, Thode D, Nielsen J. Effects of sertindole on cognition in clozapine-treated schizophrenia patients. Objective: To assess the cognitive effects of sertindole augmentation in clozapine-treated patients diagnosed with schizophrenia. Cognition is secondary outcome of the trial. Method: A 12-week, double-blinded, randomized, placebo-controlled, augmentation study of patients treated with clozapine. Participants were randomized 1:1 to receive 16 mg of sertindole or placebo as adjunctive treatment to clozapine. Results: Participants displayed substantial cognitive deficits, ranging from 1.6 standard deviation below norms at baseline to more than three standard deviations on tests of response readiness and focused attention. There were no significant differences between sertindole augmentation and placebo groups at study end. Correlation analysis of Positive and Negative Syndrome (PANSS) subscales, Global Assessment of Functioning subscale (GAF-F) and Clinical Global Impression (CGI) with 20 neurocognitive indices was conducted, but no significant correlations were found. Second, we tested change from baseline to endpoint for the PANSS, GAF-F, and CGI, vs. the concomitant changes in cognitive test performance, and found no significant correlations. Conclusion: The clozapine-treated patients displayed marked cognitive deficits at baseline. Adding sertindole did not improve or worsen cognitive functioning, which is in line with previous negative studies of the effect on cognition of augmenting clozapine treatment with another antipsychotic drug. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Schizophrenia, cognition, randomized controlled trial
in
Acta Psychiatrica Scandinavica
volume
126
issue
1
pages
31 - 39
publisher
Wiley-Blackwell
external identifiers
  • wos:000304985400004
  • scopus:84862116009
ISSN
1600-0447
DOI
10.1111/j.1600-0447.2012.01840.x
language
English
LU publication?
yes
id
1bcc7af5-eb62-43d0-80f0-372410b2fccc (old id 2895840)
date added to LUP
2012-08-01 08:51:32
date last changed
2017-11-05 04:10:02
@article{1bcc7af5-eb62-43d0-80f0-372410b2fccc,
  abstract     = {Nielsen RE, Levander S, Thode D, Nielsen J. Effects of sertindole on cognition in clozapine-treated schizophrenia patients. Objective: To assess the cognitive effects of sertindole augmentation in clozapine-treated patients diagnosed with schizophrenia. Cognition is secondary outcome of the trial. Method: A 12-week, double-blinded, randomized, placebo-controlled, augmentation study of patients treated with clozapine. Participants were randomized 1:1 to receive 16 mg of sertindole or placebo as adjunctive treatment to clozapine. Results: Participants displayed substantial cognitive deficits, ranging from 1.6 standard deviation below norms at baseline to more than three standard deviations on tests of response readiness and focused attention. There were no significant differences between sertindole augmentation and placebo groups at study end. Correlation analysis of Positive and Negative Syndrome (PANSS) subscales, Global Assessment of Functioning subscale (GAF-F) and Clinical Global Impression (CGI) with 20 neurocognitive indices was conducted, but no significant correlations were found. Second, we tested change from baseline to endpoint for the PANSS, GAF-F, and CGI, vs. the concomitant changes in cognitive test performance, and found no significant correlations. Conclusion: The clozapine-treated patients displayed marked cognitive deficits at baseline. Adding sertindole did not improve or worsen cognitive functioning, which is in line with previous negative studies of the effect on cognition of augmenting clozapine treatment with another antipsychotic drug.},
  author       = {Nielsen, R. E. and Levander, Sten and Thode, D. and Nielsen, J.},
  issn         = {1600-0447},
  keyword      = {Schizophrenia,cognition,randomized controlled trial},
  language     = {eng},
  number       = {1},
  pages        = {31--39},
  publisher    = {Wiley-Blackwell},
  series       = {Acta Psychiatrica Scandinavica},
  title        = {Effects of sertindole on cognition in clozapine-treated schizophrenia patients},
  url          = {http://dx.doi.org/10.1111/j.1600-0447.2012.01840.x},
  volume       = {126},
  year         = {2012},
}